In yesterday’s Wall Street session, X4 Pharmaceuticals Inc. (NASDAQ:XFOR) shares traded at $1.28, up 21.90% from the previous session.
8 analysts cover X4 Pharmaceuticals Inc. (NASDAQ:XFOR), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $5.00 and a low of $2.60, we find $3.50. Given the previous closing price of $1.05, this indicates a potential upside of 233.33 percent. XFOR stock price is now -33.48% away from the 50-day moving average and -10.63% away from the 200-day moving average. The market capitalization of the company currently stands at $128.29M.
The stock has received a hold rating from 0 analysts and a buy rating from 8. Brokers who have rated the stock have averaged $3.64 as their price target over the next twelve months.
With the price target of $3, Cantor Fitzgerald recently initiated with Overweight rating for X4 Pharmaceuticals Inc. (NASDAQ: XFOR).
In other news, Stewart Murray, Interim Chief Medical Officer sold 130,056 shares of the company’s stock on Aug 10. The stock was sold for $137,859 at an average price of $1.06. Upon completion of the transaction, the Interim Chief Medical Officer now directly owns 146,504 shares in the company, valued at $0.19 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 30, Chief Financial Officer Mostafa Adam S. sold 2,641 shares of the business’s stock. A total of $4,991 was realized by selling the stock at an average price of $1.89. This leaves the insider owning 80,221 shares of the company worth $0.1 million. A total of 0.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in XFOR stock. A new stake in X4 Pharmaceuticals Inc. shares was purchased by PERCEPTIVE ADVISORS LLC during the first quarter worth $5,818,000. CVI HOLDINGS, LLC invested $2,944,000 in shares of XFOR during the first quarter. In the first quarter, MONASHEE INVESTMENT MANAGEMENT LLC acquired a new stake in X4 Pharmaceuticals Inc. valued at approximately $733,000. EAM INVESTORS, LLC acquired a new stake in XFOR for approximately $727,000. SCOGGIN MANAGEMENT LP purchased a new stake in XFOR valued at around $621,000 in the second quarter. In total, there are 83 active investors with 35.00% ownership of the company’s stock.
On Friday morning X4 Pharmaceuticals Inc. (NASDAQ: XFOR) stock kicked off with the opening price of $1.0600. During the past 12 months, X4 Pharmaceuticals Inc. has had a low of $0.65 and a high of $2.58. As of last week, the company has a debt-to-equity ratio of 0.63, a current ratio of 5.00, and a quick ratio of 5.00. The fifty day moving average price for XFOR is $1.9092 and a two-hundred day moving average price translates $1.4292 for the stock.
The latest earnings results from X4 Pharmaceuticals Inc. (NASDAQ: XFOR) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.33, missing analysts’ expectations of -$0.16 by -0.17. This compares to -$0.60 EPS in the same period last year. The company reported revenue of $25.8 million for the quarter, compared to $20.57 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 25.45 percent.
X4 Pharmaceuticals Inc.(XFOR) Company Profile
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
